New tirapazamine derivatives protect cardiomyocytes from doxorubicin toxicity

• Main Authors: Korga Agnieszka, Iwan Magdalena, Matosiuk Dariusz, Rzadkowska Marzena, Szacon Elzbieta, Humeniuk Ewelina, Sysa Marcin, Ostrowska Marta, Dudka Jaroslaw
• Format: Article
• Language: English
• Published: Sciendo 2020-03-01
• Series: Current Issues in Pharmacy and Medical Sciences
• Subjects: doxorubicin; tirapazamine derivative; cardiotoxicity; triphenylphosphine cation; oxidative stress
• Online Access: https://doi.org/10.2478/cipms-2020-0001

Doxorubicin cardiotoxicity is caused by various mechanisms, most importantly by oxidative stress originating in the mitochondria. Tirapazamine is a hypoxia-activated anticancer experimental drug. Both drugs in normoxia conditions undergo univalent reduction, thus tirapazamine may compete with doxorubicin in univalent reduction enzyme uptake. Herein, tirapazamine derivatives consisted of drug molecules and alkyl chain-connected triphenylphosphine cations that bring about an accumulation in mitochondria. The aim of this study was to evaluate the interaction of newly synthesized tirapazamine derivatives with doxorubicin in rat cardiomyocytes via an vitro model. In the work, H9C2 cells were incubated with combinations of doxorubicin, tirapazamine and seven variants of tirapazamine derivatives. After 24 hours, cell viability was assessed using MTT assay and the results were confirmed by microscopic observation. Tirapazamine in all tested concentrations did not revealed significant protective activity to cardiomyocytes treated with doxorubicine. However, tirapazamine derivatives diminished the cytotoxic effect of doxorubicin regardless of concentration and alkyl chain length. Tirapazamine derivatives have shown protective effects in relation to cardiomyocytes treated with doxorubicin and the mechanism of this phenomenon must be confirmed.